Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for ...

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the market will grow ...

Rothschild & Co Redburn initiated coverage of Regeneron (REGN) with a Buy rating and $890 price target Published first on TheFly – the ultimate ...